Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

THE TRUTH ABOUT: Looking into akebia therapeutics s return on capital employed - Caught on Camera

According to Benzinga Pro data, during Q1, Akebia Therapeutics (NASDAQ:AKBA) posted sales of $61.70 million. Earnings were up 11.68%, but Akebia Therapeutics still reported an overall loss of $62.42 million. In Q4, Akebia Therapeutics brought in $59.60 million in sales but lost $70.68 million in earnings.

What Is Return On Capital Employed?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.